DOCSLIB.ORG

Myelodysplastic Syndromes (MDS)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Myelodysplastic Syndromes (MDS) Myelodysplastic Syndromes (MDS) A Guide for Patients Introduction Being diagnosed with a myelodysplastic syndrome (MDS) can be a shock, particularly when you may never have heard of it. This booklet has been written to help you understand more about MDS. It describes what the various forms are, how they are diagnosed and treated and also the expected outcome (prognosis). It will also provide information on coping with the emotional impact of an MDS diagnosis. For more information, your Bowen, Honorary Professor of haematologist or clinical nurse Myeloid Leukaemia Studies and specialist will be able to provide Consultant Haematologist at St advice that is specific to your James’s Institute of Oncology. The diagnosis. booklet has also been reviewed by patients and we are grateful This booklet has been to Chris Dugmore and Claudia written by Dr Sally Killick, Richards for their valuable Consultant Haematologist; Dr contribution. Dominic Culligan, Consultant Haematologist; Philip Alexander, Throughout this booklet you will Counsellor and Cognitive see a number of quotations. These Behaviour Psychotherapist; are the real experiences of MDS Geke Ong and Janet Hayden, patients and will hopefully help Clinical Nurse Specialists; and you to understand your situation peer reviewed by Professor David a bit better. If you would like any information on the sources used for this booklet, please email [email protected] for a list of references. Version 2 Printed: 11/2018 2 www.leukaemiacare.org.uk Review date: 10/2021 In this booklet Introduction 2 In this booklet 3 Acknowledgements 4 About Leukaemia Care 6 MDS at a glance 10 Who gets MDS and why? 12 Signs and symptoms 13 Diagnosis 14 What are the types of MDS? 17 What is the prognosis of MDS? 19 Treatment of MDS 22 The psychological impact of MDS 33 Living with MDS 44 MDS specialist centres and 53 other useful organisations Glossary 58 Appendix 60 Helpline freephone 08088 010 444 3 Acknowledgements This booklet has been compiled assistance and advice to by MDS UK Patient Support Group, patients and families affected Leukaemia Care and Bloodwise by myelodysplastic syndromes. in a joint collaboration. Although We offer a helpline, newsletter, you are reading the version website, chat forum and meeting supplied by Leukaemia Care, groups nationwide to facilitate all of the wording is the same contact with other MDS patients in each organisation’s booklet. and their families. Based at King’s This booklet does not endorse College Hospital, MDS UK is the any specific product or brand only national support group solely – any names mentioned are for dedicated to MDS. information only. About Leukaemia Care Acknowledgements and further Leukaemia Care is dedicated to thanks to The Irish Cancer Society providing information, support for their permission to use and advice to blood cancer information and images from patients, their carers and loved their MDS booklet. ones. This booklet has been endorsed Whether they need a listening ear by the Leukaemia & Lymphoma NI from our Patient Advocacy team, charity. a buddy to chat to who has been Leukaemia & Lymphoma NI funds in a similar position, a visit to research into the causes and one of our support groups or good cures of leukaemia, lymphoma quality, trusted information about and myeloma in Northern Ireland. a diagnosis, treatment or side effects, we are here for them all. Contributing charities About Bloodwise About MDS UK We’re the UK’s leading blood MDS UK Patient Support cancer research charity. We fund Group provides information, research to improve treatment 4 www.leukaemiacare.org.uk and care for people living with all types of blood cancer, and we provide anyone affected with information and support. Helpline freephone 08088 010 444 5 About Leukaemia Care Leukaemia Care is a national charity dedicated to ensuring that people affected by blood cancer have access to the right information, advice and support. Our services found on our website at www. leukaemiacare.org.uk/support- Helpline and-information/help-and- Our helpline is available 9.00am - resources/information-booklets/ 10.00pm on weekdays and Support Groups 9.00am - 12.30pm on Saturdays. If you need someone to talk to, Our nationwide support groups call 08088 010 444 are a chance to meet and talk to other people who are going Nurse service through a similar experience. We have two trained nurses on For more information about a hand to answer your questions support group local to your area, and offer advice and support, go to www.leukaemiacare.org. whether it be through emailing uk/support-and-information/ [email protected], support-for-you/find-a-support- over the phone on 08088 010 444 group/ or via LiveChat. Buddy Support Patient Information Booklets We offer one-to-one phone We have a number of patient support with volunteers who have information booklets like had blood cancer themselves this available to anyone who or been affected by it in some has been affected by a blood way. You can speak to someone cancer. A full list of titles – both who knows what you are going disease specific and general through. For more information information titles – can be on how to get a buddy call 6 www.leukaemiacare.org.uk 08088 010 444 or email service, LiveChat (9am-5pm [email protected] weekdays). Online Forum Campaigning and Advocacy Our online forum, Leukaemia Care is involved in www.healthunlocked.com/ campaigning for patient well- leukaemia-care, is a place being, NHS funding and drug for people to ask questions and treatment availability. If you anonymously or to join in the would like an update on any of discussion with other people in a the work we are currently doing or similar situation. want to know how to get involved, email advocacy@leukaemiacare. Patient and carer conferences org.uk Our nationwide conferences provide an opportunity to Patient magazine ask questions and listen to Our quarterly magazine patient speakers and medical includes inspirational patient professionals who can provide and carer stories as well as valuable information and support. informative articles by medical professionals. To subscribe go Website to www.leukaemiacare.org.uk/ You can access up-to-date communication-preferences/ information on our website, www.leukaemiacare.org.uk, as well as speak to one of our care advisers on our online support Helpline freephone 08088 010 444 7 Your details: Date of diagnosis My diagnosis/type of MDS Cytogenic results Date Details and Good, normal or poor chromosome affected 8 www.leukaemiacare.org.uk Name Contact details Consultant haematologist Specialist nurse GP Haematology day care unit Haematology inpatient ward Emergency contact number Helpline freephone 08088 010 444 9 Myelodysplastic syndromes at a glance What are This results in the number of blood cells in the bloodstream myelodysplastic being reduced. This is referred to syndromes? as a ‘cytopenia’. Some patients The myelodysplastic syndromes, have just one type of blood cell or MDS for short, are a group of that is low (such as red blood diseases in which the production cells), however, sometimes MDS of blood cells by the bone marrow can cause a reduction in all the is faulty. It is a type of cancer and types of blood cells. When this sometimes may be referred to as occurs, it is called ‘pancytopenia’. bone marrow failure. The bone marrow is located inside some of Can MDS lead to any your bones and it is the factory other conditions? where blood cells are made. It is In addition to low blood counts, here where the problem lies. the myelodysplastic syndromes The bone marrow makes three share a common tendency to main types of blood cells: develop into acute myeloid leukaemia (AML) over time. In 1. Red blood cells that carry MDS, the bone marrow has a oxygen around the body number of immature abnormal cells called blasts. In some 2. White blood cells that fight patients with MDS the number infections of blasts increases with time. 3. Platelets that prevent bleeding Leukaemia (AML) is defined as having more than 20% blast cells. What causes MDS? The risk of AML occurring depends In MDS, the bone marrow is on the type of MDS, but some usually more active than normal, patients may never progress to yet the blood cells it produces AML. are not healthy (we refer to that as ‘dysplastic’); do not work as You can find out more about well as they should and many AML in factsheets and booklets die either before they reach the available from Bloodwise and bloodstream or shortly afterwards. Leukaemia Care. 10 www.leukaemiacare.org.uk Is MDS a cancer? You do not need to MDS is a form of bone marrow learn everything about cancer, although its progression into leukaemia does not always MDS at once. You can occur. It is included in the World keep this booklet and Health Organisation Classification refer back to it, reading of Haematopoietic (blood and different sections as bone marrow) Tumours. and when you’re ready. Helpline freephone 08088 010 444 11 Who gets MDS and why? MDS is a rare disease. It may be previous chemotherapy or diagnosed at any age but it is very radiotherapy. rare in children and young adults. Inherited disorders – very This booklet deals with MDS • rarely, MDS can be inherited or occurring in adults. may develop from another rare The typical age for patients to blood disorder. For this reason, develop MDS is around 75 years young patients may be tested old. About 9 out of 10 patients for any diseases that are linked are over 50 years at the time to MDS. However, for the vast of diagnosis. Men are slightly majority of patients, MDS will more likely than women to be not be passed down to children diagnosed with MDS.
Load more

Recommended publications
  • The Clinical Management of Chronic Myelomonocytic Leukemia Eric Padron, MD, Rami Komrokji, and Alan F
    The Clinical Management of Chronic Myelomonocytic Leukemia Eric Padron, MD, Rami Komrokji, and Alan F. List, MD Dr Padron is an assistant member, Dr Abstract: Chronic myelomonocytic leukemia (CMML) is an Komrokji is an associate member, and Dr aggressive malignancy characterized by peripheral monocytosis List is a senior member in the Department and ineffective hematopoiesis. It has been historically classified of Malignant Hematology at the H. Lee as a subtype of the myelodysplastic syndromes (MDSs) but was Moffitt Cancer Center & Research Institute in Tampa, Florida. recently demonstrated to be a distinct entity with a distinct natu- ral history. Nonetheless, clinical practice guidelines for CMML Address correspondence to: have been inferred from studies designed for MDSs. It is impera- Eric Padron, MD tive that clinicians understand which elements of MDS clinical Assistant Member practice are translatable to CMML, including which evidence has Malignant Hematology been generated from CMML-specific studies and which has not. H. Lee Moffitt Cancer Center & Research Institute This allows for an evidence-based approach to the treatment of 12902 Magnolia Drive CMML and identifies knowledge gaps in need of further study in Tampa, Florida 33612 a disease-specific manner. This review discusses the diagnosis, E-mail: [email protected] prognosis, and treatment of CMML, with the task of divorcing aspects of MDS practice that have not been demonstrated to be applicable to CMML and merging those that have been shown to be clinically similar. Introduction Chronic myelomonocytic leukemia (CMML) is a clonal hemato- logic malignancy characterized by absolute peripheral monocytosis, ineffective hematopoiesis, and an increased risk of transformation to acute myeloid leukemia.
    [Show full text]
  • Pancytopenia; Study for Clinical Features and Etiological Pattern at Tertiary Care Settings in Abbottabad
    The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-2253 PANCYTOPENIA; STUDY FOR CLINICAL FEATURES AND ETIOLOGICAL PATTERN AT TERTIARY CARE SETTINGS IN ABBOTTABAD Dr. Atif Sitwat Hayat1, Dr. Abdul Haque Khan2, Dr. Ghulam Hussian Baloch3, Dr.Naila Shaikh4 1. MBBS, M.D (Medicine) Assistant Professor of Medicine, ABSTRACT... Background: Pancytopenia is an important hematological problem encountered Isra University Hospital, Hala Road in our day-to-day clinical practice. The aim of our study was to evaluate clinical features and Hyderabad, Sind, Pakistan. 2. MBBS, FCPS (Medicine) etiological pattern of pancytopenia at tertiary care settings in Abbottabad. Methods: This Associate Professor of Medicine prospective study was conducted at Northern Institue of Medical Sciences (NIMS) and Ayub Liaquat University of Medical and Health Sciences Jamshoro, Sind, Pakistan. Teaching Hospital Abbottabad from 25th August 2009 to 31st July 2010. A total of 85 patients 3. MBBS, Dip Card, M.D (Medicine) fulfilling the criteria of pancytopenia were randomly selected by time-based sampling. Associate Professor of Medicine Pancytopenia was diagnosed by anemia (hemoglobin ≤ 10.0g/dl), leucopenia (WBC ≤ 4.0×109/L) Liaquat University of Medical and 9 Health Sciences Jamshoro, Sind, Pakistan. and thrombocytopenia (platelets ≤ 150×10 /L). All data has been entered and analyzed by SPSS 4. MBBS, DCP version 10.0. Results: Out of 85 patients, 62(72.94%) were males and 23(27.05%) females with Senior Lecturer, Liaquat University of Medical and M to F ratio of 2.69:1. The mean age (±SD) of males was 30.20±15.42 years, while that of females Health Sciences Jamshoro, Sind, Pakistan.
    [Show full text]
  • Section 8: Hematology CHAPTER 47: ANEMIA
    Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited.
    [Show full text]
  • Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant
    Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children’s Research Hospital Departments of Hematology, Patient Education, and Biomedical Communications. Funds were provided by St. Jude Children’s Research Hospital, ALSAC, and a grant from the Plough Foundation. This document is not intended to take the place of the care and attention of your personal physician. Our goal is to promote active participation in your care and treatment by providing information and education. Questions about individual health concerns or specifi c treatment options should be discussed with your physician. For more general information on sickle cell disease, please visit our Web site at www.stjude.org/sicklecell. Copyright © 2009 St. Jude Children’s Research Hospital How did bone marrow (stem cell) transplants begin for children with sickle cell disease? Bone marrow (stem cell) transplants have been used for the treatment and cure of a variety of cancers, immune system diseases, and blood diseases for many years. Doctors in the United States and other countries have developed studies to treat children who have severe sickle cell disease with bone marrow (stem cell) transplants. How does a bone marrow (stem cell) transplant work? 2 In a person with sickle cell disease, the bone marrow produces red blood cells that contain hemoglobin S. This leads to the complications of sickle cell disease. • To prepare for a bone marrow (stem cell) transplant, strong medicines, called chemotherapy, are used to weaken or destroy the patient’s own bone marrow, stem cells, and infection fi ghting system.
    [Show full text]
  • Outcomes for Patients with Chronic Lymphocytic Leukemia and Acute Leukemia Or Myelodysplastic Syndrome
    Leukemia (2016) 30, 325–330 © 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16 www.nature.com/leu ORIGINAL ARTICLE Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome FP Tambaro1, G Garcia-Manero2, SM O'Brien2, SH Faderl3, A Ferrajoli2, JA Burger2, S Pierce2, X Wang4, K-A Do4, HM Kantarjian2, MJ Keating2 and WG Wierda2 Acute leukemia (AL) and myelodysplastic syndrome (MDS) are uncommon in chronic lymphocytic leukemia (CLL). We retrospectively identified 95 patients with CLL, also diagnosed with AL (n = 38) or MDS (n = 57), either concurrently (n =5)or subsequent (n = 90) to CLL diagnosis and report their outcomes. Median number of CLL treatments prior to AL and MDS was 2 (0–9) and 1 (0–8), respectively; the most common regimen was purine analog combined with alkylating agent±CD20 monoclonal antibody. Twelve cases had no prior CLL treatment. Among 38 cases with AL, 33 had acute myelogenous leukemia (AML), 3 had acute lymphoid leukemia (ALL; 1 Philadelphia chromosome positive), 1 had biphenotypic and 1 had extramedullary (bladder) AML. Unfavorable AML karyotype was noted in 26, and intermediate risk in 7 patients. There was no association between survival from AL and number of prior CLL regimens or karyotype. Expression of CD7 on blasts was associated with shorter survival. Among MDS cases, all International Prognostic Scoring System (IPSS) were represented; karyotype was unfavorable in 36, intermediate in 6 and favorable in 12 patients; 10 experienced transformation to AML. Shorter survival from MDS correlated with higher risk IPSS, poor-risk karyotype and increased number of prior CLL treatments.
    [Show full text]
  • Myelodysplastic Syndromes Overview and Types
    cancer.org | 1.800.227.2345 About Myelodysplastic Syndromes Overview and Types If you have been diagnosed with a myelodysplastic syndrome or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Myelodysplastic Syndromes? ● Types of Myelodysplastic Syndromes Research and Statistics See the latest estimates for new cases of myelodysplastic syndromes in the US and what research is currently being done. ● Key Statistics for Myelodysplastic Syndromes ● What's New in Myelodysplastic Syndrome Research? What Are Myelodysplastic Syndromes? Myelodysplastic syndromes (MDS) are conditions that can occur when the blood- forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells. MDS is considered a type of cancer1. Normal bone marrow 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Bone marrow is found in the middle of certain bones. It is made up of blood-forming cells, fat cells, and supporting tissues. A small fraction of the blood-forming cells are blood stem cells. Stem cells are needed to make new blood cells. There are 3 main types of blood cells: red blood cells, white blood cells, and platelets. Red blood cells pick up oxygen in the lungs and carry it to the rest of the body. These cells also bring carbon dioxide back to the lungs. Having too few red blood cells is called anemia. It can make a person feel tired and weak and look pale. Severe anemia can cause shortness of breath. White blood cells (also known as leukocytes) are important in defending the body against infection.
    [Show full text]
  • The Hematological Complications of Alcoholism
    The Hematological Complications of Alcoholism HAROLD S. BALLARD, M.D. Alcohol has numerous adverse effects on the various types of blood cells and their functions. For example, heavy alcohol consumption can cause generalized suppression of blood cell production and the production of structurally abnormal blood cell precursors that cannot mature into functional cells. Alcoholics frequently have defective red blood cells that are destroyed prematurely, possibly resulting in anemia. Alcohol also interferes with the production and function of white blood cells, especially those that defend the body against invading bacteria. Consequently, alcoholics frequently suffer from bacterial infections. Finally, alcohol adversely affects the platelets and other components of the blood-clotting system. Heavy alcohol consumption thus may increase the drinker’s risk of suffering a stroke. KEY WORDS: adverse drug effect; AODE (alcohol and other drug effects); blood function; cell growth and differentiation; erythrocytes; leukocytes; platelets; plasma proteins; bone marrow; anemia; blood coagulation; thrombocytopenia; fibrinolysis; macrophage; monocyte; stroke; bacterial disease; literature review eople who abuse alcohol1 are at both direct and indirect. The direct in the number and function of WBC’s risk for numerous alcohol-related consequences of excessive alcohol increases the drinker’s risk of serious Pmedical complications, includ- consumption include toxic effects on infection, and impaired platelet produc- ing those affecting the blood (i.e., the the bone marrow; the blood cell pre- tion and function interfere with blood cursors; and the mature red blood blood cells as well as proteins present clotting, leading to symptoms ranging in the blood plasma) and the bone cells (RBC’s), white blood cells from a simple nosebleed to bleeding in marrow, where the blood cells are (WBC’s), and platelets.
    [Show full text]
  • Your Blood Cells
    Page 1 of 2 Original Date The Johns Hopkins Hospital Patient Information 12/00 Oncology ReviseD/ RevieweD 6/14 Your Blood Cells Where are Blood cells are made in the bone marrow. The bone marrow blood cells is a liquid that looks like blood. It is found in several places of made? the body, such as your hips, chest bone and the middle part of your arm and leg bones. What types of • The three main types of blood cells are the red blood cells, blood cells do the white blood cells and the platelets. I have? • Red blood cells carry oxygen to all parts of the body. The normal hematocrit (or percentage of red blood cells in the blood) is 41-53%. Anemia means low red blood cells. • White blood cells fight infection. The normal white blood cell count is 4.5-11 (K/cu mm). The most important white blood cell to fight infection is the neutrophil. Forty to seventy percent (40-70%) of your white blood cells should be neutrophils. Neutropenia means your neutrophils are low, or less than 40%. • Platelets help your blood to clot and stop bleeding. The normal platelet count is 150-350 (K/cu mm). Thrombocytopenia means low platelets. How do you Your blood cells are measured by a test called the Complete measure my Blood Count (CBC) or Heme 8/Diff. You may want to keep track blood cells? of your blood counts on the back of this sheet. What When your blood counts are low, you may become anemic, get happens infections and bleed or bruise easier.
    [Show full text]
  • Automatic Blood Cell and CRP Counter with Three-Part Differential
    FEATURE ARTICLE Automatic Blood Cell and CRP Counter with Three-Part Differential Measurement of White Blood Cells The LC-170 CRP FEATURE ARTICLE Automatic Blood Cell and CRP Counter with Three-Part Differential Measurement of White Blood Cells, The LC-170 CRP Yasuo Yamao WBC, RBC, Hct Electrical impedance method Hgb CRP Cyanmethemoglobin method Latex immunoturbidmetry WBC (White blood cells) LYM% MON% GRA% CRP quantitative LC-170CRP (Lymphocyte %) (Monocyte %) (Granulocyte %) analysis LYM# MON# GRA# (C-reactive protein) (Lymphocyte No.) (Monocyte No.) (Granulocyte No.) RBC (Red blood cells) PLT (Platelets) Hgb(Hemoglobin) Pct (Plateletcrit) Hct (Hematocrit) MPV (Mean Platelet Volume) MCV (Mean Corpuscular Volume) PDW (Platelet Distribution Width) MCH (Mean Corpuscular Hemoglobin) MCHC (Mean Corpuscular Hemoglobin Concentration) RDW (Red Blood Cell Distribution Width) Example of results Abstract The LC-l70 CRP automatic blood cell and CRP counter, developed by Horiba, is capable of simultaneously measuring all 19 C-reactive protein (CRP) density parameters and counting red blood cells, platelets, and three types of white blood cell: lymphocytes, monocytes, and granulocytes. As clinicians demand ever-higher precision measurements, a need has developed for clinical test machines having excellent operational and cost performance. This compact machine should make a powerful tool for initial diagnosis of inflammatory and infectious diseases, especially at small- and mid-size medical institutions. 20 Technical Reports 1 Introduction 2 Measurement Principles To prevent an explosion of medical costs as Japanese The LC-170 CRP uses the electrical impedance method society ages and fewer children are born, the Ministry of to count blood cells, the cyanmethemoglobin method to Health, Labor, and Welfare is pursuing a thorough reform measure hemoglobin concentration, and latex of the medical insurance system, including “preventing immunoturbidimetry to measure CRP concentration.
    [Show full text]
  • Thrombotic Thrombocytopenicpurpurawith
    Med J 955 - 957 The of Postgrad (1990) 66, © Fellowship Postgraduate Medicine, 1990 Postgrad Med J: first published as 10.1136/pgmj.66.781.955 on 1 November 1990. Downloaded from Thrombotic thrombocytopenic purpura with terminal pancytopenia Soo-Chin Ng' and B.A. Adam2 1Haematology Division, Department ofPathology, 2Department ofMedicine, Medical Faculty, University ofMalaya, 59100 Kuala Lumpur, Malaysia Summary: A 27 year old housewife developed thrombotic thrombocytopenic purpura during the twelfth week of pregnancy. She had partial response to initial plasma infusion and subsequent plasmapheresis. However, her clinical course was complicated by the development ofsevere pancytopenia the consequence of a hypocellular marrow. She succumbed to septicaemic shock one month after diagnosis. The development ofhypocellular marrow in thrombotic thrombocytopenicpurpura has not been reported before. Introduction Thrombotic thrombocytopenic purpura (TTP) is a 30.8 x 109/l with a slight left shift and the platelet rare disorder characterized in its form count was 10 x The direct complete by 109/1. Coomb's test was Protected by copyright. the pentad of thrombocytopenia, microangio- negative. Peripheral blood film confirmed marked pathic haemolytic anaemia (MAHA), fluctuating thrombocytopenia and a striking number of frag- neurological abnormalities, renal impairment and mented red cells and occasional nucleated red cells fever.' We report a patient with TTP in pregnancy were present. Her prothrombin time, partial who developed terminal pancytopenia secondary thromboplastin time, thrombin time and fibrin- to hypocellular marrow. ogen level were within normal limits. Bone marrow examination showed a normocellular marrow with erythroid hyperplasia and presence of normal Case report granulopoiesis and megakaryopoiesis. Urinalysis revealed microscopic haematuria.
    [Show full text]
  • Essential Thrombocythemia Facts No
    Essential Thrombocythemia Facts No. 12 in a series providing the latest information for patients, caregivers and healthcare professionals www.LLS.org • Information Specialist: 800.955.4572 Introduction Highlights Essential thrombocythemia (ET) is one of several l Essential thrombocythemia (ET) is one of a related “myeloproliferative neoplasms” (MPNs), a group of closely group of blood cancers known as “myeloproliferative related blood cancers that share several features, notably the neoplasms” (MPNs) in which cells in the bone “clonal” overproduction of one or more blood cell lines. marrow that produce the blood cells develop and All clonal disorders begin with one or more changes function abnormally. (mutations) to the DNA in a single cell; the altered cells in l ET begins with one or more acquired changes the marrow and the blood are the offspring of that one (mutations) to the DNA of a single blood-forming mutant cell. Other MPNs include polycythemia vera and cell. This results in the overproduction of blood cells, myelofibrosis. especially platelets, in the bone marrow. The effects of ET result from uncontrolled blood cell l About half of individuals with ET have a mutation production, notably of platelets. Because the disease arises of the JAK2 (Janus kinase 2) gene. The role that this from a change to an early blood-forming cell that has the mutation plays in the development of the disease, capacity to form red cells, white cells and platelets, any and the potential implications for new treatments, combination of these three cell lines may be affected – and are being investigated. usually each cell line is affected to some degree.
    [Show full text]
  • Neutrophils (A.K.A
    Neutrophils (a.k.a. leukocyte, granulocyte, white blood cell, WBC) blood cells on a microscope slide showing the lobed nucleus of two neutrophils a 3-d drawing of a neutrophil This chart shows how blood cells are produced in the bone marrow from “stem cells” and how we organize them into groups. By Mikael Häggström The Mul(faceted Func(ons of Neutrophils Tanya N. Mayadas,1 Xavier Cullere,1 and Clifford A. Lowell2 “Neutrophils and neutrophil-like cells are the major pathogen-fighKng immune cells in organisms ranging from slime molds to mammals. Central to their funcKon is their ability to be recruited to sites of infecKon, to recognize and phagocytose (eang foreign objects like bacteria) microbes, and then to kill pathogens through a combinaon of cytotoxic mechanisms.” Form • average diameter of 12-15 micrometers (µm) in peripheral blood smears • in suspension, neutrophils have an average diameter of 8.85 µm • mulK-lobed shape nucleus • survive for only 8–12 h in the circulaon and up to 1–2 days in Kssues • Neutrophils will show increasing segmentaon (many segments of nucleus) as they mature. A normal neutrophil should have 3-5 segments. • Neutrophils account for approximately 50-70% of all white blood cells (leukocytes) Func(on • first line of host defense against a wide range of infecKous pathogens including bacteria, fungi, and protozoa • Neutrophils are generated at a rate of 1011 per day, which can increase to 1012 per day during bacterial infection. • Researchers once believed that neutrophils were present only during the most acKve phase of an infecKon, funcKoning as pathogen killers.
    [Show full text]